CSF2 and cancer: JX-594 (Pexa-Vec; Jennerex Inc.), a thymidine kinase (TK, J2R) gene-inactivated Wyeth strain VV expressing GM-CSF, selectively targets cancer cells and has shown promising safety and efficacy in phase II trials using intratumoral or intravenous delivery to treat soft tissue sarcomas (13, 14).